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Acute topical treatment of human skin with retinoic acid 
(RA) results in a pleiotropic response, some aspects of which 
are mimicked by non-specific irritants. To identify reliable 
cutaneous markers of retinoid action, it is important to deter-
mine which aspects of this response are specifically due to the 
presence of RA. We have previously demonstrated a rapid 
and pronounced increase in steady-state cellular RA-binding 
protein II (CRABP-I1)mRNA levels after topical RA treat-
ment. Here we characterize the dose dependence and kinetics 
of this response, and compare the effects of a well-known 
irritant, sodium dodecylsulfate (SDS), to those ofRA and its 
vehicle. The induction of CRABP-I1 mRNA in response to 
0.1 % RA cream was maximal by 16 h (elevenfold relative to 
untreated skin), and persisted at near-maximal levels (eight-
fold) for up to 4 d. RA was potent in eliciting this response, as 
I t is a common clinical observation that the use of topical RA in acne and other skin conditions often leads to an erythema-tous, scaly skin response, especially early in the course of its use. Histologically, this reaction is characterized by epider-mal hyperplasia, spongiosis, and a compacted stratum cor-
neum, with only limited infiltration of inflammatory cells, mostly 
CD4+ T cells [1,2]. · These observations have been confirmed by 
several groups of investigators [3,4]. Similar cutaneous effects are 
observed after dietary retinoid administration in the mouse [5] , sug-
gesting that the effects seen after topical treatment are primarily due 
to the presence of retinoid. However, some perturbation of the skin 
is inevitable after topical treatment, and many of the same responses 
have been observed after experimental skin irritation, using agents 
such as sodium dodecylsulfate (SDS) [6], tape stripping [7], abrasion 
[8]. or application of organic solvents [9]. Therefore, to better un-
derstand the cutaneous effects of topical RA and to facilitate devel-
opment of new retinoids with fewer cutaneous side effects, it is 
important to determine which aspects of this response are specifi-
cally due to the presence of RA. 
Cellular retinoic acid-binding protein II (CRABP-II) is selec-
tively expressed (relative to CRABP-I) in normal adult human 
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approximately half-maximal stimulation was observed after 
16 h of treatment with 0.001 % RA. Treatment for 4 d with 
0.1 % RA cream versus 2% SDS in RA vehicle resulted in 
nearly identical levels of cutaneous erythema, spongiosis, and 
epidermal thickening. However, the CRABP-II mRNA re-
sponse to 2% SDS was no greater than that observed in re-
sponse to vehicle alone (2.9 times relative to occluded skin 
control at 4 d). SDS also had no effect upon either CRABP-II 
ot RAR-fJ mRNA levels in quiescent human dermal fibro-
blasts in vitro, whereas RA elicited both responses at 1000-
times lower concentrations than SDS. Taken together, these 
data identify the CRABP-II mRNA response as a reliable, 
rapid, and selective marker for retinoid activity in human 
skin.] Invest DermatoI100:356-359, 1993 
[10,11] and mouse [12] skin. Unlike the nuclear retinoic acid recep-
tors, expression of CRABP-II is markedly increased after topical RA 
treatment [10,13,14], and could therefore serve as a marker for 
cutaneous retinoid activity in vivo. However, CRABP-II is also 
markedly overexpressed in psoriatic lesions [13,15,16], suggesting 
that its induction in RA-treated skin could be a secondary effect of 
the epidermal hyperplasia attendant to that disease and to RA-
treated skin. To address this issue, we have measured cutaneous 
erythema, various histologic parameters [1,2]' and CRABP-I1 
mRNA levels after various times of continuous occluded topical 
treatment with RA cream (0.1 %), 2% SDS in RA vehicle, and RA 
vehicle alone relative to untreated, non-occluded skin. In addition, 
we have investigated the dose dependence of the CRABP-I1 re-
sponse to RA in vivo. Finally, we have compared the dose depen-
dence of the CRABP-II and RAR-/l mRNA responses to RA versus 
SDS treatment in quiescent dermal fibroblasts ill vitro. The results 
clearly demonstrate that the cutaneous actions of topical RA cannot 
be ascribed solely to an irritant response, and identify CRABP-II as a 
rapid and reliable marker of retinoid activity in human skin. 
MATERIALS AND METHODS 
Treatment Protocols All in vivo experiments were carried out 
with the approval of the Institutional Review Board, University of 
Michigan Medical Center. For comparisons of RA and SDS treat-
ment, after obtaining informed consent three 3 X 9 cm patches of 
buttock skin were selected for treatment with RA cream (0.1 %, 
Ortho Pharmaceuticals, Raritan, NJ), 2% SDS in RA vehicle (pre-
pared by mixing 1/9 volume of a 20% aqueous solution of SDS 
• Griffiths CEM, Finkel LJ, Tranfaglia MG, Hamilton TA, Voorhees J): 
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[Sigma, St. Louis, MO] with RA vehicle), or RA vehicle alone. The 
treated areas were then occluded under plastic wrap, sealed with 
tape, and left in l?lace for 16, 48, or 96 h. (In six volunteers, occlu-
sion alone [96 hJ was substituted for SDS treatment) . After these 
intervals, the treatment sites were assessed for erythema using a 0 - 9 
scale, 0 representing absent, and 9 maximal erythema. Histologic 
evaluation of some of these specimens for epidermal thickness, 
spongiosis, and stratum corneum compaction has been reported sep-
arately [1]. * The three treatment sites, and a comparably sized strip 
of untreated, non-occluded skin were the.n rem~ved at a depth of 
0.2 mm using a CastrovleJo keratome and ImmedIately snap-frozen 
in liquid nitrogen. 
For assessment of dose response, RA powder (Ortho Pharmaceu-
ticals) was dissolved at various concentrations in a liq~i~ vehicle 
consisting of70% ethanol, 30% propylene glycol, contall1ll1g buty-
lated hydroxytolue.ne as a preservative .Aliquots (100 Ill) contai~ing 
various concentratIons of RA or velllcle alone were applIed 111 a 
blinded fashion to 3 X 6 em patches of skin using a micropipette 
and occluded with plastic wrap. After 16 h, keratome biopsies were 
performed as described above. Punch biopsies (4 mm) were ob-
tained from each site, and histologic eva luation of these biopsies was 
performed as described. * 
RNA Isolation and Northern Blot Analysis of Treated 
Skin Total RNA was isolated from snap-frozen biopsies stored at 
-70°C until use. The guanidinium isothionate-cesium chloride 
procedure was used as previously described [17], except that cesium 
trifluoroacetate (Pharmacia) was used according to the manufac-
turer's instructions. Forty micrograms total RNA (determined by 
OD260) was size-fractionated by electrophoresis over 1 % formalde-
hyde-agarose gels and transferred to derivatized nylon membrane 
(Zeta-Probe~ Bio-Rad, Richmond, CA). Blots were se<;Iuentially hy-
bridized agall1st 32P-Iabeled CRABP-II and cyclophl1ll1 probes pre-
pared by random priming, and quantitated using a phosphorimager 
(MolecularDynamics, Sunnyvale, CA) as previous~y described (10). 
HybridizatIOn to the CRABP-II probe was normaltzed to cycloplll-
lin as previously described [10,16 -18], and results we.re expres.se? as 
fold-change relative to untreated skin of the same patient. Statistical 
analysis was performed using either a two-tailed paired t test or a 
repeated measur~s analysis of variance with Tukey's method for 
multiple compansons, as appropnate. 
Analysis of CRABP-II mRNA Levels in RA and SDS-
Treated Human Dermal Fibroblasts Secondary cultures of 
normal adult human dermal fibroblasts were prepared as previously 
described [18], propagated in McCoys SA medium (Sigma) conta~n­
ing 10% fetal calf serum and antibiotics, and used in the tlurd 
through sixth passage. At confluence, medium was changed and the 
cultures were maintained for an additional 48 to 72 h. Cu ltures 
were treated with RA or SDS dissolved in DMSO vehicle, which 
was present in all treated and control cu ltures at a final concentra-
tion of 0.1 %. After 48 h, RNA was isolated using RNAzol (Cll1na/ 
Biotecx, Friendswood, TX) as previously described [18]. Blotting 
and hybridization to CRABP-II, cyclophilin, and RAR-P [18] 
probes was performed as described above. 
RESULTS 
As summarized in Fig 1, 2% SDS and 0.1 % RA each produced a 
consistent, marked, and significant increase in erythema relative to 
vehicle after 96 h, which was not significantly different between 
the two agents. Little or no erythema was observed in response to 
vehicle after 96 h, nor to any of the treatments after 16 or 48 h. 
As shown in Fig 2, CRABP-II mRNA levels were markedly and 
significantly increased by RA treatment at all time points studied 
(16, 48, and 96 h). Despite the induction of marked erythema by 
SOS treatment, Fig 2 also demonstrates that induction of CRABP-II 
mRNA by this agent was markedly and significantly less than that 
obtained in response to RA, and in fact was slightly less than that 
obtained in response to vehicle alone at all time points studied. 
Occlusion alone had no effect upon CRABP-II mRNA levels rela-
tive to dry skin (Fig 2). However, 4 d of vehicle treatment under 
CRABP-II RESPONSE IN HUMAN SKIN 357 
6 DORY * 
w 
f;J VEH 
a: 5 ~SOS 
0 
.RA () 
en 4 
« MEAN = SEM 
~ 3 w 
J: 
I- 2 >-
a: 
w 
0 
16 HOURS 2 DAYS 
(n=10) (n=7) 
Figure 1. Time course of erythema response to vehicle, SOS, and RA 
treatment. Opell bars (ORY), untreated skin without occlusion. Horizolltal 
striped bars (VEH), RA vehicle under occlusion. Diago/wl striped bars (SOS), 
2% SOS in RA vehicle under occlusion. Solid bars (RA), 0.1 % RA cream 
under occlusion. Error bars, mean ± SEM. Asterisks, significant differences 
observed for VEH versus SOS and VEH versus RA (p < 0.02 by analYSis 
of variance). All other comparisons were not Significant. 
occlusion resulted in significantly higher CRABP-II mRNA levels 
than did occlusion alone (2.9 times'r = 0.05, n = 6). 
Figure 3 summarizes the results 0 experiments designed to test 
the dose dependence of the cutaneous CRABP-II mRNA response 
to topical RA. These experiments made use of a different vehicle 
(70% ethanol, 30% propylene glycol), because RA cream formula-
tions were not available at all concentrations to be tested. Treatment 
was for 16 h, because induction CRABP-II transcripts was found to 
be maximal by this time point. Under these conditions, RA stimu-
lated CRABP-II mRNA approximately fivefold at a concentration 
of 0.001 %, a concentration that had no detectable clinical or histo-
logic effect relative to vehicle after 4 d of treatment. * As expected 
from the time course study, * there was no increase in the histologic 
parameters of epidermal thickness, spongiosis, or stratum corneum 
compaction after 16 h of treatment (data not shown). Although 
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Figure 2. Time course of CRABP-Il mRNA response to vehicle, SOS, and 
RA treatment. Horizo l/tal striped bars, vehkle; diagollal striped bars, 2% SOS in 
vehicle; solid bars, 0.1 % RA cream; vertically hatched bars, occlusion alone. p 
values for various comparisons, made using a two-tailed paired t test, are 
as follows. For 16 h, vehicle versus SOS, p = 0.335, n = 14; vehicle 
versus RA, p = 0.0001, n = 10; SOS versus RA, p = 0.00005, n = 14. For 
2 d, vehicle versus SOS, p = 0.97, n = 7; vehicle versus RA, p = 0.04, 
n = 7; SOS versus RA, p = 0.04, n = 7. For 4 d, vehicle versus SOS, 
p = 0.21, n = 7; vehicle versus RA, p = 0.006, n = 16, SOS versus RA, 
p = 0.0006, n = 7; occlusion versus vehicle, p = 0.05, n = 6. The number 
of specimens used to calculate SEM values differ in some cases from those 
used for significance testing due to limited numbers of paired specimens 
for certain comparisons. The numbers of specimens used to calculate the 
SEM values shown are as follows. For 16 h, vehicle and RA, n = 14; SOS, 
n = 10. For 2 d, n = 7 for all. For4 d, vehicle and RA, n = 16; SOS, n = 7, 
occlusion alone, n = 6. 
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Figure 3. Dose response of ill vivo RA treatment. Volunteers were treated 
for 16 h with the indicated concentrations of RA or vehicle under occlu-
sion. Data represent mean ± SEM of normalized CRABP-Il mRNA levels 
detennined as described in Materials and-Methods. Statistical analysis was 
by repeated measures analysis of variance wi th Tukey's method for multi-
pie comparisons. Asterisk, p < 0.05 versus vehicle. All differences be-
tween groups were significant at the 0.05 level with the exception of 
0.005% RA and 0.025% RA, which were not Significantly different com-
pared to each other. 
higher concentrations of RA were not tested using this vehicle 
system, comparison to the data in Fig 2 indicates that an approxi-
mately half-maximal CRABP-I1 response is obtained at 1 % of the 
high est concentration used clinically (0.1 %). 
Induction of CRABP-I1 mRNA by RA in postconfluent human 
dermal fibroblasts (FB) has been reported previously [10,18,19] . 
Under these conditions, SDS was unable to stimulate CRABP-I1 or 
RAR-P transcripts in postconfluent FB at concentrations a thou-
sandfold higher than required for their induction by RA (Fig 4) . 
This result was not due to lack of effect ofSDS because as previously 
reported [20] increasing the SDS concentration to 50 )LM resulted in 
complete loss of fibroblast viability (data not shown). 
DISCUSSION 
CRABP-I1 has recently been identified in human skin and isolated 
by molecular cloning [10,11] . Like its murine counterpart, human 
CRABP-Il is selectively expressed at the mRNA level in adult skin 
and is induced by RA treatment [10-14] . t Although its exact func-
tion remains enigmatic, the observation that the CRABP-I1 re-
sponse to RA IS conserved strongly suggests that it is directly in-
volved in the mediation of cutaneous retinoid effects. Therefore, we 
hypothesized that increased CRABP-I1 might be a relatively spe-
cific response to RA. To test this hypothesis, we determined 
whether application of SDS, a well-known irritant, could induce 
the CRABP-Il response. 
Several lines of evidence indicate that the CRABP-Il mRNA 
response cannot be explained as a non-specific concomitant of skin 
irritation. As shown in Figs 1 and 2, 2% SDS and 0.1 % RA caused 
comparable increases in erythema. However, SDS did not increase 
CRABP-I1 expression above the background referable to vehicle 
treatment alone, whereas RA treatment consistently and markedly 
did so. The response was rapid; the greatest induction observed in 
these studies occurred at 16 h (Fig 2). Moreover, marked induction 
has been observed as early as 6 h after topical RA t~eatment. * In 
addition, RA was high ly potent in inducing this response, being 
half-maximal in the presence of 0.001 % RA (Fig 3). Finally, in 
quiescent fibroblasts, addition of SDS to the medium had no effects 
on CRABP-Il mRNA levels at concentrations 1000 times greater 
than that required for its induction by RA (Fig 4). Moreover, the 
t Reynolds NJ, Griffiths CEM, Tavakkol A, Talwar HS, Voorhees lJ, 
Fisher G) : Retinoic acid metabolites exhibit biological activity in human 
keratinocytes, mouse melanoma cells and hairless mouse skin in vivo 
(abstr). J Invest Dermatol 98:562A, 1992. 
* A. Tavakkol (personal communication). 
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Figure 4. Northern blot of CRABP-II response to RA versus 50S treat-
ment in quiescent adult human dermal fibroblasts. Serial re-hybridiza-
tions of the same blot are shown. Sizes of bands shown (in kb) are indi-
cated to the left, and probes used are indicated to the right. Results shown 
are representative of three independent experiments using adult fibro-
blasts from three different donors, and two additional experiments using 
neonatal foreskin fibroblasts . 
failure of SDS to induce RAR-P, which is known to contain a 
functional retinoic acid response element in its 5' regulatory region 
[21,22], indicates that SDS is not acting to release endogenous stores 
of RA or its metabolic precursors under these conditions. 
These results complement and extend our recent histologic and 
clinical time-course comparison of SDS and RA treatment. * We 
have previously shown that SDS and RA induce a similar histologic 
response after 4 d [1]. However, the time-course comparison dem-
onstrated that RA induced epidermal thickening, stratum corneum 
compaction, spongiosis, and mitotic figures more rapidly than did 
SDS. * Thus, both the CRABP-Il and histologic results demonstrate 
that RA elicits cutaneous responses that cannot be accounted for by 
irritant or vehicle effects alone. 
A modest (two- to threefold) increase in CRABP-Il transcripts 
was frequently observed in response to vehicle treatment, and could 
not be accounted for by the effects of occlusion alone. Vehicle 
treatment alone consistently fai led to produce erythema, suggesting 
that the effects of vehicle on CRABP-Il expression, like those ofRA 
itself, cannot be accounted for by irritation alone. Recent studies of 
epidermal barrier function have demonstrated that disruption of the 
barrier leads to a pleiotropic response reminiscent of that of RA 
treatment, including increased DNA synthesis [9], epidermal cyto-
kine production [23], and epidermal trafficking of immune/inflam-
matory cells. § Systemic retinoid treatment has been shown to re-
duce epidermal barrier function in the hairless mouse [24], and 
topical RA treatment has been associated with increased transepider-
mal water loss, a hallmark of barrier function, in humans [25J. It is 
possible that altered barrier function represents a common mecha-
nism underlying some, but not all , responses to RA, its vehicle, and 
irritants. Further insights into the mechanism of this vehicle effect 
might be gained by analysis of the induction of CMBP-I1 mRNA 
in response to various defined vehicle components, and by further 
studies of trans epidermal water loss under these treatment condi-
tions. 
Regardless of mechanism, the studies described here and e1se-
where* definitively demonstrate that topical retinoids elicit rapid, 
dose-dependent cutaneous responses that cannot be ascribed to irrita-
tion or vehicle effects alone, and which can be monitored by assess-
§ Proksch E, Sterry W: Epidermal Langerhans cell density correlates 
with permeability barrier (abstr). J Invest DermatoI90:553A, 1992. 
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ing the levels ofCRABP-II mRNA. Moreover, similar responses are 
observed in fibroblasts, providing a complementary in vitro assay of 
cellular responses to RA. These developments will allow further 
correlation of the cutaneous effects of various retinoids with their 
recepror binding and transactivation properties. This information 
wi ll , in turn, enable development of response profiles for receptor-
specific retinoids, with the objective of separation of their therapeu-
tic and irritant effects. Given the documented beneficial effects of 
retinoids on various dermatoses including acne, skin cancer, and 
diseases of keratinization in add ition to photoaging, this informa-
tion will be of major benefit for future dermatologic therapies. 
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